Detalimogene voraplasmid - enGene
Alternative Names: Bladder cancer gene therapy - enGene; DDX® intravesicle gene therapy - enGene; Detalimogene; EG-70Latest Information Update: 17 Dec 2024
Price :
$50 *
At a glance
- Originator enGene
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action DDX58 protein inhibitors; Gene transference; Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Bladder cancer
- Research Urogenital cancer
Most Recent Events
- 23 Oct 2024 Pharmacodynamics data from a preclinical trial in Bladder cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 26 Sep 2024 Preliminary efficacy and adverse events data from the phase I/II LENGEND trial in Bladder cancer released by enGene
- 14 Jun 2024 EnGene plans to file BLA for Bladder cancer in mid 2026